The Current Ratio of Beyondspring Inc (BYSI) is
1.54.
Current Ratio compares a firm's current assets to its current liabilities to assess short-term liquidity. A ratio above 1.0 typically indicates a strong ability to meet obligations.
| Date |
Value |
| 2025-12-31 |
1.54
|
| 2024-12-31 |
2.60
|
| 2023-12-31 |
2.31
|
| 2022-12-31 |
5.24
|
| 2021-12-31 |
4.96
|
| 2020-12-31 |
8.24
|
| 2019-12-31 |
4.06
|
| 2018-12-31 |
0.36
|
| 2017-12-31 |
6.75
|
| 2016-12-31 |
5.64
|
| Ticker |
Name |
Value |
|
AVRO
|
AVROBIO Inc
|
15.78
|
|
SNSE
|
Sensei Biotherapeutics Inc
|
5.06
|
|
SPRB
|
Spruce Biosciences, Inc.
|
5.17
|
|
GMDA
|
Gamida Cell Ltd
|
2.16
|
|
INZY
|
Inozyme Pharma Inc
|
3.56
|
|
NCNA
|
NuCana PLC
|
5.60
|
|
ONCT
|
Oncternal Therapeutics Inc
|
6.94
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
2.90
|
|
950200.KQ
|
Psomagen Inc
|
1.67
|
|
ABBV
|
AbbVie Inc.
|
0.67
|
|
CRNX
|
Crinetics Pharmaceuticals, Inc.
|
12.32
|
|
VKTX
|
Viking Therapeutics, Inc.
|
9.33
|
|
NLTX
|
Neoleukin Therapeutics Inc
|
8.93
|
|
AMGN
|
Amgen Inc
|
1.14
|
|
APLT
|
Applied Therapeutics Inc
|
3.11
|
|
AUTL
|
Autolus Therapeutics PLC
|
5.94
|
|
FHTX
|
Foghorn Therapeutics Inc.
|
2.73
|
|
OCX
|
OncoCyte Corp
|
1.62
|
|
APS.TO
|
Aptose Biosciences Inc
|
0.78
|
|
CRDF
|
Cardiff Oncology, Inc.
|
3.67
|
|
CUE
|
Cue Biopharma, Inc.
|
2.74
|
|
MRNA
|
Moderna, Inc.
|
3.29
|
|
950160.KQ
|
Kolon TissueGene Inc
|
0.24
|
|
ACET
|
ADICET Bio, Inc.
|
7.47
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
4.13
|
|
SPRO
|
Spero Therapeutics, Inc.
|
7.59
|
|
ETNB
|
89bio Inc
|
13.19
|
|
FBRX
|
Forte Biosciences, Inc.
|
3.88
|
|
GERN
|
Geron Corporation
|
4.66
|
|
GILD
|
Gilead Sciences, Inc.
|
1.55
|
|
CBMG
|
Cellular Biomedicine Group Inc
|
1.44
|
|
LCTX
|
Lineage Cell Therapeutics Inc
|
5.20
|
|
SMMT
|
Summit Therapeutics Inc.
|
9.87
|
|
950220.KQ
|
Neoimmunetech Inc
|
3.08
|
|
AGLE
|
Aeglea Bio Therapeutics Inc
|
4.24
|
|
BLU.TO
|
BELLUS Health Inc
|
22.42
|